New drug combo shows promise against deadly brain cancers
NCT ID NCT06806228
First seen Nov 18, 2025 · Last updated Jun 19, 2026 · Updated 26 times
Summary
This early-phase study tests whether adding the experimental drug S-Gboxin to standard radiation and chemotherapy can help people with glioblastoma or diffuse midline glioma, two aggressive brain cancers. Ten participants whose tumors have returned or worsened will receive the combination and be monitored with brain scans and survival tracking. The goal is to see if S-Gboxin can shrink tumors or improve outcomes, while checking for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOSARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Kazakh Institute of Oncology and Radiology
Almaty, 490 078, Kazakhstan
-
National Cancer Institute
Kyiv, 33/43, Ukraine
-
Tbilisi Cancer Centre
Tbilisi, 0198, Georgia
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.